12.91
1.16 (9.87%)
| Penutupan Terdahulu | 11.75 |
| Buka | 12.93 |
| Jumlah Dagangan | 175,109 |
| Purata Dagangan (3B) | 95,106 |
| Modal Pasaran | 338,469,216 |
| Harga / Jualan (P/S) | 5.03 |
| Harga / Buku (P/B) | 25.19 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Feb 2025 |
| Margin Keuntungan | -95.47% |
| Margin Operasi (TTM) | -70.63% |
| EPS Cair (TTM) | -2.23 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 43.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 373.16% |
| Nisbah Semasa (MRQ) | 3.73 |
| Aliran Tunai Operasi (OCF TTM) | -51.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -33.68 M |
| Pulangan Atas Aset (ROA TTM) | -45.37% |
| Pulangan Atas Ekuiti (ROE TTM) | -152.44% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Avita Medical, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.50 |
|
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.97% |
| % Dimiliki oleh Institusi | 23.45% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 25.00 (D. Boral Capital, 93.65%) | Beli |
| Median | 21.00 (62.67%) | |
| Rendah | 12.00 (Piper Sandler, -7.05%) | Pegang |
| Purata | 19.33 (49.73%) | |
| Jumlah | 2 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 12.59 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 24 Dec 2024 | 21.00 (62.66%) | Beli | 12.91 |
| D. Boral Capital | 24 Dec 2024 | 25.00 (93.65%) | Beli | 12.91 |
| Piper Sandler | 08 Nov 2024 | 12.00 (-7.05%) | Pegang | 11.95 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 23 Dec 2024 | Pengumuman | AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds |
| 19 Dec 2024 | Pengumuman | AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market |
| 18 Dec 2024 | Pengumuman | AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 25 Nov 2024 | Pengumuman | AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference |
| 12 Nov 2024 | Pengumuman | AVITA Medical Announces Exclusive Distribution Agreement to Expand to Australia and New Zealand |
| 08 Nov 2024 | Pengumuman | AVITA Medical to Host Investor Webinar Briefing |
| 07 Nov 2024 | Pengumuman | AVITA Medical Reports Third Quarter Financial Results |
| 10 Oct 2024 | Pengumuman | AVITA Medical to Announce Third Quarter 2024 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |